12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cartistem regulatory update

Medipost said the Korea Food and Drug Administration approved Cartistem to treat osteoarthritis. Cartistem consists of allogeneic mesenchymal...

Read the full 67 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >